W
Wendt Michael D
Researcher at AbbVie
Publications - 39
Citations - 4208
Wendt Michael D is an academic researcher from AbbVie. The author has contributed to research in topics: Nucleophile & Solvent effects. The author has an hindex of 12, co-authored 39 publications receiving 4023 citations. Previous affiliations of Wendt Michael D include Idun Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf,Steven W. Elmore,Alexander R. Shoemaker,Robert C. Armstrong,David J. Augeri,Barbara A. Belli,Milan Bruncko,Thomas L. Deckwerth,Jürgen Dinges,Philip J. Hajduk,Mary K. Joseph,Shinichi Kitada,Stanley J. Korsmeyer,Stanley J. Korsmeyer,Kunzer Aaron R,Anthony Letai,Chi Li,Michael J. Mitten,David G. Nettesheim,Shi Chung Ng,Paul Nimmer,Jacqueline M. O'Connor,Anatol Oleksijew,Andrew M. Petros,John C. Reed,Wang Shen,Stephen K. Tahir,Craig B. Thompson,Kevin J. Tomaselli,Baole Wang,Wendt Michael D,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg +33 more
TL;DR: Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation.
Journal ArticleDOI
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Milan Bruncko,Thorsten Oost,Barbara A. Belli,Hong Ding,Mary K. Joseph,Kunzer Aaron R,Darlene Martineau,Mcclellan William J,Michael J. Mitten,Shi-Chu Ng ng,Paul Nimmer,Tilman Oltersdorf,Cheol-Min Park,Andrew M. Petros,Alexander R. Shoemaker,Xiaohong Song,Wang Xilu,Wendt Michael D,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +21 more
TL;DR: Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.
Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208
Souers Andrew J,Joel D. Leverson,Erwin R. Boghaert,Scott L. Ackler,Nathaniel D. Catron,Jun Chen,Brian D. Dayton,Hong Ding,Sari H. Enschede,Wayne J. Fairbrother,David C. S. Huang,Sarah G. Hymowitz,Sha Jin,Seong Lin Khaw,Peter Kovar,Lloyd T. Lam,Jackie Lee,Heather Maecker,Kennan C. Marsh,Kylie D. Mason,Michael J. Mitten,Paul Nimmer,Anatol Oleksijew,Chang H. Park,Cheol-Min Park,Darren C. Phillips,Andrew W. Roberts,Deepak Sampath,John F. Seymour,Morey L. Smith,Gerard M. Sullivan,Stephen K. Tahir,Chris Tse,Wendt Michael D,Yu Xiao,John Xue,Haichao Zhang,Rod A. Humerickhouse,Saul H. Rosenberg,Steven W. Elmore +39 more
Journal ArticleDOI
Discovery and Structure−Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo
Wendt Michael D,Wang Shen,Kunzer Aaron R,Mcclellan William J,Milan Bruncko,Thorsten Oost,Hong Ding,Mary K. Joseph,Haichao Zhang,Paul Nimmer,Shi-Chung Ng,Alexander R. Shoemaker,Andrew M. Petros,Anatol Oleksijew,Kennan C. Marsh,Joy Bauch,Tilman Oltersdorf,Barbara A. Belli,Darlene Martineau,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +21 more
TL;DR: Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-X(L) function, 73R, potentiates the activity of paclitaxel and UV irradiation in vitro and potentiated the antitumor efficacy of pac litaxel in a mouse xenograft model.
Patent
N-acylsulfonamide apoptosis promoters
Milan Bruncko,Hong Ding,Steven W. Elmore,Kunzer Aaron R,Christopher L. Lynch,Mcclellan William J,Cheol-Min Park,Andrew M. Petros,Xiaohong Song,Wang Xilu,Noah Tu,Wendt Michael D +11 more
TL;DR: In this paper, Nacylsulfonamide compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases were discussed.